Summary
A bioRxiv preprint describes ST9, a designed peptide that binds claudin-5 and produces a rapid, transient and reversible increase in blood-brain barrier permeability in reported cell-based experiments.
A bioRxiv preprint describes ST9, a peptide designed to bind claudin-5 (CLDN5), a protein central to the blood-brain barrier’s sealing function. In the experiments reported by the authors, ST9 produced a rapid, transient, size-controlled and fully reversible increase in the movement of molecules through the space between brain endothelial cells.
The study combines generative protein design with atomistic simulations to create the peptide. The authors compared ST9 with f1-C5C2, an earlier CLDN5-binding peptide, and report that the two produced different patterns of tight-junction destabilisation. The work is an early-stage, cell-based and computational study rather than a clinical investigation.
How ST9 is intended to modulate the barrier
The blood-brain barrier is formed largely by specialised endothelial cells lining blood vessels in the brain. These cells are joined by tight junctions, structures that restrict the passage of substances through the gaps between neighbouring cells. This protection helps regulate the brain’s chemical environment, but it also limits access for many medicines and useful molecules circulating in the blood.
CLDN5 forms multimeric complexes within those tight junctions. The researchers designed ST9 to bind CLDN5 and compete with interactions that help maintain the junctional seal. The intended result is a temporary change in the paracellular pathway—the route between adjacent cells—rather than unrestricted passage across the barrier.
According to the preprint’s abstract, ST9 has high nanomolar affinity for CLDN5. In the reported brain-endothelial-cell experiments, the peptide caused a rapid rise in paracellular permeability that was described as size-controlled, transient and fully reversible. The authors also report that ST9 did not alter CLDN5 expression or the proteomic profile of the brain endothelial cells. They interpret these findings as evidence that ST9 destabilises tight junctions through a mechanism distinct from that of f1-C5C2.
Why controlled opening matters
A temporary and controllable change in blood-brain barrier permeability could provide a route for improving the delivery of nutrients or medicines to the brain. Duration and molecular-size control are important because a useful delivery system would need to increase access while allowing the barrier to return to its normal state.
The preprint presents ST9 as a candidate for developing next-generation blood-brain barrier-opening agents for neurological disease. Its evidence, however, is limited to the computational design work and the cell-based findings described in the record. The study does not report a clinical trial or therapeutic treatment in people, and the abstract does not provide sample size or detailed permeability measurements. Testing in living systems with defined therapeutic cargoes will be needed to determine whether the reported control can translate into practical brain-drug delivery.